NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) has issued a new draft report recommending against the histology-independent use of larotrectinib (Bayer's Vitrakvi) for advanced adult and pediatric cancer patients treated through the National Health Service (NHS), even for rare cancer types or when no other satisfactory treatment options exist.